O. Heikinheimo

No ORCID on file · 8 papers in corpus · active 1996-2023

Study types

  • article 4
  • other 2
  • peer-review 1
  • review 1

Condition tags

  • endometriosis 8
  • chronic_pelvic_pain 1
  • infertility 1
article 2023
·doi:10.22514/ejgo.2023.014

Although endometriosis could be associated with certain epithelial ovarian cancers and elevated serum cancer antigen (CA) 19-9 levels, it is difficult to diagnose endometriosis using this marker. We report an unusual case of endometriosis t…

article 2023
·doi:10.33029/2303-9698-2023-11-1-67-93
article 2022
·doi:10.1093/humrep/deac106.072

Abstract In 2005, under the auspices of ESHRE, a group of international experts evaluated the existing best evidence and published the first European guideline on the management of endometriosis. This highly successful project was the first…

article 2019
Human Reproduction ·doi:10.1093/humrep/dez074

STUDY QUESTION: Is all-cause and cause-specific mortality increased among women with surgically verified endometriosis? SUMMARY ANSWER: The all-cause and cause-specific mortality in midlife was lower throughout the follow-up among women wit…

peer-review 2019
·doi:10.7287/peerj.8135v0.1/reviews/1

Endometriosis is a chronic disease occurring during the reproductive stage of women.Although there is only limited association between endometriosis and gynecological cancers with regard to clinical features, the molecular basis of the rela…

other 2014
Human Reproduction ·doi:10.1093/humrep/det457

STUDY QUESTION: What is the optimal management of women with endometriosis based on the best available evidence in the literature? SUMMARY ANSWER: Using the structured methodology of the Manual for ESHRE Guideline Development, 83 recommend…

other 1997
Clinical pharmacokinetics ·doi:10.2165/00003088-199733010-00002

Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level. The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone.…

review 1996
Clinical obstetrics and gynecology ·doi:10.1097/00003081-199606000-00019

Use of standard estrogen-progestin contraception remains problematic in several subgroups of patients (e.g., those in whom exogenous estrogens are contraindicated, such as survivors of hormone-dependent cancer, or patients with endometriosi…